Answers are grounded in this paper and cite their sources.
Mixed methods evaluation shows improved GDM detection using fluoride-citrate tubes in Aboriginal women, highlighting implementation challenges.
Abstract BackgroundAn estimated 62% of gestational diabetes mellitus (GDM) in rural and remote Australia are missed due to preanalytical error in measuring glucose for the oral glucose tolerance test (OGTT). To address diagnostic inequity, Kimberley Aboriginal Community Control Health Organisations (ACCHOs) replaced fluoride-oxalate (FLOX) tubes with fluoride-citrate (FC) tubes that better preserve glucose in all pregnancy OGTTs in 2019. This study describes FC tube implementation and impact on GDM detection and management.MethodsA mixed methods approach was used. Acceptability, barriers, enablers and resources required to support implementation were assessed using qualitative descriptive approaches. These were mapped to the Dynamic Sustainability Framework domains of practice settings and ecological systems. A retrospective audit of antenatal records for women attending a Kimberley ACCHO (2018–2021) described maternal characteristics, OGTT (≥ 24-weeks’ gestation), GDM management, and birth outcomes over 24-months pre- (T1) and post- (T2) FC tube implementation. Outcomes using new Australian 2025 diagnostic criteria were compared to 2014 criteria (T2 only).ResultsClinicians’ initial concerns (increased GDM diagnosis, interventions at birth, low resources) were resolved when they became more confident in FC glucose measurements. The main barriers to implementation were staff turnover, pathology testing systems and supply chain issues. Of 830 eligible women, 378 (45.5%) completed an OGTT within the audit periods: 196 T1 (FLOX); 182 T2 (FC). Glucose at all OGTT time-points was 0.7 to 0.8 mmol/L higher in T2 (v T1). The 2.8-fold increase in GDM with FC tubes was largely due to increased diagnoses at the fasting sample (39.3% v 78.1% of GDM cases, P = 0.001). Seven-fold more women were recommended for pharmaceutical management of hyperglycaemia (2.6% T1 v 17.6% T2, P < 0.001). Neonatal growth-for-gestational-age and induction of labour was similar between T1 and T2. Using new higher OGTT cut-points would reduce GDM diagnoses (27.5% v 40.1%, P < 0.001), while identifying 84.4% of women requiring pharmaceutical management.ConclusionsCollection of blood into FC tubes improved identification of women requiring pharmaceutical intervention for GDM. There was no adverse impact on birth interventions. A collective approach involving healthcare practices and pathology providers to implement diagnostic strategies that improve OGTT accuracy is urgently required.
No takes yet. Share an insight, caveat, or question.
Spry et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: